Sign Up to like & get
recommendations!
0
Published in 2018 at "Psychotherapy Research"
DOI: 10.1080/10503307.2016.1277039
Abstract: Abstract Objective: Routine outcome monitoring (ROM) has been strongly endorsed by psychotherapy researchers, but has yet to achieve widespread implementation in clinical settings. This article describes the development of the Clinically Adaptive Multidimensional Outcome Survey…
read more here.
Keywords:
development clinically;
outcome;
adaptive multidimensional;
clinically adaptive ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.14251
Abstract: Hereditary angioedema (HAE) due to C1‐inhibitor deficiency (C1‐INH‐HAE) is a rare, potentially fatal, bradykinin‐mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union and 2011 in the United…
read more here.
Keywords:
experience hereditary;
hereditary angioedema;
outcome survey;
icatibant outcome ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Orphanet Journal of Rare Diseases"
DOI: 10.1186/s13023-017-0635-z
Abstract: Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare lysosomal storage disease with progressive multisystem manifestations caused by deficient activity of the enzyme iduronate-2-sulfatase. Disease-specific treatment is available in the form of…
read more here.
Keywords:
disease;
hunter outcome;
hos;
survey hos ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Clinical and Translational Allergy"
DOI: 10.1186/s13601-018-0229-4
Abstract: The objective of this analysis was to evaluate the change over time in age at first symptoms, age at diagnosis, and delay in diagnosis using data from the Icatibant Outcome Survey (IOS). Patients with a…
read more here.
Keywords:
diagnosis;
age;
time;
icatibant outcome ... See more keywords